Monitoring tumor response to therapy typically relies on changes in tumor volume. However, various functional and molecular changes, including vascular density, occur before any measurable changes in tumor size are observed. Some imaging modalities such as MRI and PET, have been used to predict response to therapy, but high costs, long imaging times, and radiation risks limit their clinical application.
Learn how researchers used ultrasound imaging to measure vascular density to assess the response of renal cell carcinoma tumors to antiangiogenic and Notch inhibition therapies earlier than the clinical gold standard for evaluating tumor volume.